Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Havas to Open New Manchester Village at Circle Square

The global communications group will unite six agencies under one roof in a purpose-built, hybrid workspace at the heart of Manchester’s innovation district

Havas Lynx

- PMLiVE

Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study

Almost one million new cases of gastric cancer are diagnosed globally every year

EU flag

EC approves Biocon Biologics’ denosumab biosimilars Vevzuo and Evfraxy

An estimated 32 million people aged 50 years and over in Europe were living with osteoporosis in 2019

- PMLiVE

Current market challenges are redefining the biotech landscape

Short-term uncertainty is slowing investment activity, but the long-term outlook remains strong

Maximize Conference Impact Virtually – Engaging Your Advisors Creatively

Extend the impact of scientific conferences! Discover how to creatively empower your advisors to share patient cases and evidence, sparking rich discussions on clinical implications and research questions. Drive deeper...

Impetus Digital

- PMLiVE

AstraZeneca’s Imfinzi regimen approved by EC to treat muscle-invasive bladder cancer

More than 35,000 people in five major European countries were treated for the disease last year

- PMLiVE

FDA approves Dizal’s oral therapy Zegfrovy to treat advanced lung cancer

Around 226,650 new cases of lung cancer are expected to be diagnosed in the US this year

- PMLiVE

Leveraging AI to supercharge early commercialisation strategy

How integrating AI across the commercialisation process can drive better outcomes

- PMLiVE

Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval

The rare inherited disease affects more than 109,000 people worldwide

Biogen Idec building

Biogen initiates phase 3 study of felzartamab in kidney disease patients

Approximately 36,000 people in the US are affected by primary membranous nephropathy

- PMLiVE

Sepsis and the impact of antibiotic resistance

A WHO report emphasises the serious global impact of antimicrobial resistance, which exacerbates the substantial burden of sepsis on patients, HCPs and health systems

EU flag

EC approves Jazz Pharmaceuticals’ Ziihera for advanced biliary tract cancer

Approximately 26% of biliary tract cancer patients globally have HER2-positive disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links